← Human Trials & Peer-Reviewed Studies
Effect of transdermal nicotine patches on cigarette smoking: a double blind crossover study
Plain-language guide to PMID 1570391 (1992): double-blind randomized controlled trial study of Therapeutic nicotine (patch, non-peptide) in 30 subjects.
Key Facts
- PMID
- 1570391
- Journal
- Psychopharmacology
- Year
- 1992
- Study type
- Randomized Controlled Trial
- Authors
- Foulds J et al. (6 authors)
- DOI
- 10.1007/BF02245429
What This Study Did, in Plain Language
What Was Tested
Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.
The effect of transdermal nicotine patches on ad libitum cigarette smoking was examined in 30 subjects by measuring behavioural, biochemical and subjective aspects of smoking during a week of smoking without patches, and then a week each of nicotine and placebo patches in a randomised double blind crossover design.
Who Took Part
According to the abstract, 30 subjects were involved.
PubMed indexes the participants as adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
The subjects were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.
As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.
Each person switched between Therapeutic nicotine (patch, non-peptide) and the comparison at some point, usually with a gap in between.
What Was Measured
The effect of transdermal nicotine patches on ad libitum cigarette smoking was examined in 30 subjects by measuring behavioural, biochemical and subjective aspects of smoking during a week of smoking without patches, and then a week each of nicotine and placebo patches in a randomised double blind crossover design.
Topics PubMed links to this paper include Administration, Cutaneous, Nicotine, Smoking and Smoking Cessation.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 30 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1992 (Psychopharmacology), a journal based in Germany.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.